Targeting angiogenesis in colorectal cancer tyrosine kinase inhibitors

Sheetal Mehta Kircher*, Halla S. Nimeiri, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalReview article

14 Scopus citations


Colorectal cancer is commonly diagnosed throughout the world, and treatment options have greatly expanded over the last 2 decades. Targeting angiogenesis has been a major focus of study in a variety of malignancy types. Targeting angiogenesis has been achieved by several mechanisms in colorectal cancer, including use of antiangiogenic small molecule tyrosine kinase inhibitors (TKIs). There have been many attempts and failures to prove efficacy of TKIs in the treatment of colorectal cancer including sorafenib, sunitinib, vatalanib, and tivozanib. Regorafenib was the first TKI to demonstrate efficacy and is an orally active inhibitor of angiogenic (including the vascular endothelial growth factor receptors 1, 2, and 3), stromal, and oncogenic receptor tyrosine kinases. There are ongoing investigations of both regorafenib and ninetanib; however, there remains a critical need to better understand novel combinations with TKIs that could prove more efficacious than available options.

Original languageEnglish (US)
Pages (from-to)182-189
Number of pages8
JournalCancer Journal (United States)
Issue number3
StatePublished - Jan 1 2016


  • Angiogenesis inhibitors
  • Colorectal neoplasms
  • Drug therapy
  • Protein-tyrosine kinases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting angiogenesis in colorectal cancer tyrosine kinase inhibitors'. Together they form a unique fingerprint.

  • Cite this